Acelrx pharmaceuticals reports full year and fourth quarter 2022 financial results and provides corporate update

Divestment of dsuvia® to alora pharmaceuticals expected to close the week of april 3, 2023 acelrx advancing its proprietary niyad™ nafamastat program with fda breakthrough designation in line with a strategic focus on late-stage assets near-term corporate milestones expected by the end of q2 2023 include niyad emergency use authorization submission and the filing of a new drug application for fedsyra™, the first of two pre-filled syringe product candidates $20.8 million in cash and short-term investments as of december 31, 2022 webcast and conference call to be held today at 4:30 p.m. edt hayward, calif.
ACRX Ratings Summary
ACRX Quant Ranking